Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH). Akero Therapeutics Announces …

5 天之前 · (RTTNews) - Akero Therapeutics, Inc. (AKRO), Monday, announced encouraging preliminary topline Week-96 results from a phase IIb trial of its investigational drug …

3 天之前 · SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational …

5 天之前 · Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease. The drug, known as EFX, helped …

5 天之前 · Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including …

Akero is a clinical-stage company developing transformational medicines for people with serious metablic diseases such as MASH. Akero Therapeutics Announces Week 96 Results from …

Akero's lead drug candidate, efruxifermin (EFX) has been engineered to mimic the biological activity of FGF21, which regulates multiple metabolic pathways. Akero Therapeutics …

2025年1月13日 · Efruxifermin (EFX), Akero’s lead product candidate for MASH, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity …

Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing.

4 天之前 · Akero Therapeutics announced statistically significant results from a Phase 2b trial of its lead therapeutic candidate efruxifermin (EFX) this week, a fibroblast growth factor 21 …